Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Carol H. Wysham, Jay Lin & Louis Kuritzky. (2017) Safety and efficacy of a glucagon-like peptide-1 receptor agonist added to basal insulin therapy versus basal insulin with or without a rapid-acting insulin in patients with type 2 diabetes: results of a meta-analysis. Postgraduate Medicine 129:4, pages 436-445.
Read now
Read now
Jodi Strong, Davida Kruger & Lucia Novak. (2017) Insulin glargine 300 units/mL: a guide for healthcare professionals involved in the management of diabetes. Current Medical Research and Opinion 33:4, pages 785-793.
Read now
Read now
Articles from other publishers (13)
Anand Shankar. (2021) An Efficacy and Safety Study of Remogliflozin in Obese Indian Type 2 Diabetes Mellitus Patients Who Were Inadequately Controlled on Insulin Glargine Plus other Oral Hypoglycemic Agents. Current Diabetes Reviews 17:7.
Crossref
Crossref
Cem Onur KIRAÇ, Suleyman IPEKCİ, Süleyman BALDANE, Hüseyin TEZCAN & Levent KEBAPCİLAR. (2020) Kontrol altında olmayan tip 2 diyabetes mellitus hastalarında insülin tedavisinden eksenatid bazlı tedaviye geçişin etkinliği. Cukurova Medical Journal 45:3, pages 820-826.
Crossref
Crossref
Stefan Pscherer, Helmut Anderten, Martin Pfohl, Andreas Fritsche, Anja Borck, Katrin Pegelow, Peter Bramlage & Jochen Seufert. (2019) Titration of insulin glargine 100 U/mL when added to oral antidiabetic drugs in patients with type 2 diabetes: results of the TOP-1 real-world study. Acta Diabetologica 57:1, pages 89-99.
Crossref
Crossref
Erin K. Buysman, Tao Fan, Cori Blauer-Peterson & Lesley-Ann Miller-Wilson. (2018) Glycaemic impact of treatment intensification in patients with type 2 diabetes uncontrolled with oral antidiabetes drugs or basal insulin. Endocrinology, Diabetes & Metabolism 1:3, pages e00019.
Crossref
Crossref
Philip D. Home, Bo Ahrén, Jane E.B. Reusch, Marc Rendell, Peter N. Weissman, Deborah T. Cirkel, Diane Miller, Philip Ambery, Molly C. Carr & Michael A. Nauck. (2017) Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice 131, pages 49-60.
Crossref
Crossref
Peter Bramlage, Tobias Bluhmki, Holger Fleischmann, Matthias Kaltheuner, Jan Beyersmann, Reinhard W Holl & Thomas Danne. (2017) Determinants of weight change in patients on basal insulin treatment: an analysis of the DIVE registry. BMJ Open Diabetes Research & Care 5:1, pages e000301.
Crossref
Crossref
Olga Montvida, Kerenaftali Klein, Sudhesh Kumar, Kamlesh Khunti & Sanjoy K. Paul. (2017) Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: A real-world study in 66 583 patients. Diabetes, Obesity and Metabolism 19:1, pages 108-117.
Crossref
Crossref
U. Anyanwagu, J. Mamza, R. Donnelly & I. Idris. (2016) Comparison of cardiovascular and metabolic outcomes in people with type 2 diabetes on insulin versus non-insulin glucose-lowering therapies (GLTs): A systematic review and meta-analysis of clinical trials. Diabetes Research and Clinical Practice 121, pages 69-85.
Crossref
Crossref
John R. WhiteJr.Jr.. (2016) Advances in Insulin Therapy: A Review of New Insulin Glargine 300 Units/mL in the Management of Diabetes. Clinical Diabetes 34:2, pages 86-91.
Crossref
Crossref
Stephen A. Brunton, Davida F. Kruger & Martha M. Funnell. (2016) Role of Emerging Insulin Technologies in the Initiation and Intensification of Insulin Therapy for Diabetes in Primary Care. Clinical Diabetes 34:1, pages 34-43.
Crossref
Crossref
Jennifer L. Rosselli, Shana N. Archer, Nathan K. Lindley & Lakesha M. Butler. (2015) U300 Insulin Glargine. Journal of Pharmacy Technology 31:5, pages 234-242.
Crossref
Crossref
Chantal Mathieu, R. Ravi Shankar, Daniel Lorber, Guillermo Umpierrez, Fan Wu, Lei Xu, Gregory T. Golm, Melanie Latham, Keith D. Kaufman & Samuel S. Engel. (2015) A Randomized Clinical Trial to Evaluate the Efficacy and Safety of Co-Administration of Sitagliptin with Intensively Titrated Insulin Glargine. Diabetes Therapy 6:2, pages 127-142.
Crossref
Crossref
Dragana Lovre & Vivian Fonseca. (2015) Benefits of timely basal insulin control in patients with type 2 diabetes. Journal of Diabetes and its Complications 29:2, pages 295-301.
Crossref
Crossref